永和流体智控股份有限公司 独立董事2024年度述职报告 （刘水兵） 本人（刘水兵）作为永和流体智控股份有限公司（以下简称"公司"或"永和智控"） 的独立董事，在2024年度严格按照《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公司治理准则》 《上市公司独立董事管理办法》等相关法律法规的规定及《永和流体智控股份有限公司章 程》（以下简称《公司章程》）的要求，认真行使法律所赋予的权利，忠实勤勉地履行 了独立董事的职责，及时了解公司的日常经营信息，积极出席公司2024年度召开的相关会 议，对董事会审议的相关事项发表了独立意见，充分发挥独立董事的独立作用，维护了公 司和股东、特别是社会公众股股东的利益。现将2024年度本人履行独立董事职责情况向 各位股东汇报如下； 一、独立董事的基本情况 本人刘水兵，男，1972年12月出生，中国国籍，无永久境外居留权。曾在贵州特 驱新农业有限公司担任财务总监。现任四川省天府云数据科技有限责任公司财务总监， 吉峰三农科技服务股份有限公司独立董事，永和流体智控股份有限公司第五届董事会 独立董事。 作为公司的独立董事，本人任职符合 ...

永和流体智控股份有限公司 二、2024年度履职情况 （一）2024年度出席股东大会、董事会及其专门委员会、独立董事会专门会议的 情况 独立董事2024年度述职报告 2024年度，公司董事会、股东大会等各项会议的召集召开符合法定程序，重大经 营决策事项和其他重大事项均履行了相关的审批程序。本人出席会议的情况如下： （陈禹） 1 本人（陈禹）作为永和流体智控股份有限公司（以下简称"公司"或"永和智控"）的 独立董事，在2024年度严格按照《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司治理准则》《上市公 司独立董事管理办法》等相关法律法规的规定及《永和流体智控股份有限公司章程》（以 下简称《公司章程》）的要求，认真行使法律所赋予的权利，忠实勤勉地履行了独立董 事的职责，及时了解公司的日常经营信息，积极出席公司2024年度召开的相关会议，对董 事会审议的相关事项发表了独立意见，充分发挥独立董事的独立作用，维护了公司和股东、 特别是社会公众股股东的利益。现将2024年度本人履行独立董事职责情况向各位股东汇 报如下； 一、独立董事的基本情况 1、出席董事会、股 ...

公司于近日收到三位独立董事提交的《关于独立性的自查报告》，公司董 事会对三位独立董事的独立性情况进行了评估，并出具如下意见： 公司三位独立董事盛毅先生、陈禹女士、刘水兵先生严格遵守《公司法》、 《上市公司治理准则》和《上市公司独立董事管理办法》等法律法规对独立董 事的任职要求，持续保持独立性，在2024年度不存在影响独立性的情形。 永和流体智控股份有限公司董事会 关于独立董事2024年度保持独立性情况的专项意见 2024年，永和流体智控股份有限公司（以下简称"公司"）董事会共有三位 在任独立董事，分别为盛毅先生、陈禹女士、刘水兵先生。 盛毅先生、陈禹女士、刘水兵先生在2024年度任职时间均为2024年1月1日 —2024年12月31日。 永和流体智控股份有限公司董事会 2025年4月28日 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥149,482,777.24, a decrease of 32.14% compared to ¥220,292,138.44 in the same period last year[5] - The net loss attributable to shareholders was ¥19,607,575.14, an improvement of 15.30% from a loss of ¥23,150,361.37 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.04, showing a 20.00% improvement from -¥0.05 in the same period last year[5] - The net loss attributable to the parent company is ¥355,175,781.94, compared to a loss of ¥335,568,206.80 in the previous period[22] - The company reported a net loss of ¥34,632,759.10, compared to a net loss of ¥24,074,305.95 in the previous period, indicating an increase in losses of approximately 44.5%[24] - Operating income was reported at a loss of ¥31,517,315.11, which is a deterioration from the previous loss of ¥22,698,832.98, reflecting a decline of about 38.7%[24] - Total comprehensive income amounted to a loss of ¥34,508,545.19, compared to a loss of ¥24,079,361.03 in the prior period, representing an increase in losses of approximately 43.3%[24] Cash Flow - The net cash flow from operating activities was ¥15,723,282.84, a significant increase of 179.56% compared to a negative cash flow of ¥19,761,711.86 in the same period last year[5] - Cash flow from operating activities generated a net inflow of ¥15,723,282.84, a significant improvement compared to a net outflow of ¥19,761,711.86 in the previous period[27] - The company recorded cash inflows from financing activities totaling ¥127,111,087.91, down from ¥166,251,000.00 in the prior period, indicating a decrease of about 23.5%[28] - The company’s total operating cash inflows were ¥207,674,781.09, compared to ¥233,012,707.68 in the previous period, reflecting a decline of approximately 10.9%[27] - The company’s total cash outflows from operating activities were ¥191,951,498.25, down from ¥252,774,419.54 in the previous period, indicating a decrease of about 24%[27] - The ending balance of cash and cash equivalents was ¥268,931,534.15, an increase from ¥226,618,411.33 at the end of the previous period, reflecting a growth of approximately 18.7%[28] - Cash and cash equivalents increased to ¥269,374,510.67 from ¥209,381,286.68, representing a growth of 28.7%[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,529,589,526.42, reflecting a slight increase of 0.82% from ¥1,517,137,376.53 at the end of the previous year[5] - Total assets increased to ¥1,529,589,526.42 from ¥1,517,137,376.53, a growth of 0.8%[22] - Total liabilities increased to ¥1,065,962,753.21 from ¥1,024,628,186.10, an increase of 4.0%[21] - Non-current assets decreased to ¥910,524,903.50 from ¥932,479,509.33, a decline of 2.3%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,518[13] - The largest shareholder, Cao Deli, holds 9.65% of shares, totaling 43,004,034 shares, with 4,500,000 shares pledged[13] - The second-largest shareholder, Chen Xianyun, holds 7.34% of shares, totaling 32,717,104 shares[13] - The top ten shareholders hold a significant portion of the company's shares, with the top three alone accounting for 22.51%[13] - The company has not disclosed any related party relationships among the top shareholders[13] - The company has a total of 0 preferred shareholders at the end of the reporting period[14] Operational Metrics - Accounts receivable decreased by 24.42% to ¥115,460,025.40 from ¥152,774,864.14, primarily due to a decline in sales[9] - Inventory decreased to ¥145,635,576.80 from ¥152,145,786.18, a reduction of 4.3%[20] - Short-term borrowings increased to ¥168,290,000.00 from ¥131,936,634.08, an increase of 27.5%[21] - The company experienced a 2009.23% increase in investment losses, reporting -¥1,311,521.60 compared to -¥62,180.00 in the previous year[10] - The company reported a significant increase in prepayments, which rose by 560.34% to ¥14,402,633.31, attributed to increased advance payments for equipment[9] Equity Transactions - The company is proceeding with the third public transfer of 100% equity of its wholly-owned subsidiary Chengdu Shanshui Shang Hotel Co., Ltd., with a starting price of 16,698.864 million RMB[16] - The company and its wholly-owned subsidiary, Zhejiang Yonghe Zhikong Technology Co., Ltd., will provide mutual guarantees for a total amount not exceeding 50 million RMB[17] - The total amount of shares reduced by the general manager, Xian Zhongdong, is 650,000 shares, accounting for 0.1458% of the total share capital, at an average price of 5.17 RMB per share[18] - The company has not found any interested buyers for the equity transfer during the public announcement period[16]

Financial Performance - The company's operating revenue for 2024 was ¥823,160,452.49, a decrease of 13.19% compared to ¥948,221,814.92 in 2023[22] - The net profit attributable to shareholders for 2024 was -¥297,254,575.33, representing a decline of 90.42% from -¥156,106,491.93 in 2023[22] - The cash flow from operating activities for 2024 was -¥50,728,043.36, a significant decrease of 316.59% compared to ¥23,420,977.21 in 2023[22] - The basic earnings per share for 2024 was -¥0.68, down 88.89% from -¥0.36 in 2023[22] - Total assets at the end of 2024 were ¥1,517,137,376.53, a decrease of 19.29% from ¥1,879,683,626.66 at the end of 2023[22] - The net assets attributable to shareholders at the end of 2024 were ¥518,159,919.89, down 34.68% from ¥793,205,425.83 at the end of 2023[22] - The company reported a total profit amounted to CNY -342.37 million, down 86.80% year-on-year[49] - The valve and pipe fittings business generated CNY 702.70 million, accounting for 85.37% of total revenue, with a year-on-year decrease of 7.45%[56] - The medical services and other industries contributed CNY 118.47 million, representing 14.39% of total revenue, down 19.77% year-on-year[56] Market Opportunities - The global plumbing and heating market is projected to grow, with China's market expected to reach approximately $21.9 billion by 2027, growing at a compound annual growth rate (CAGR) of 7.8% from 2020 to 2027[36] - The aging population in China is significant, with 31.03 million people aged 60 and above, representing 22.0% of the total population, indicating a growing market for cancer treatment services[38] - The number of new cancer diagnoses in China reached 4.82 million, accounting for 24.1% of global cases, highlighting the substantial demand for cancer treatment solutions[38] - Approximately 70% of cancer patients require radiotherapy at different stages of their disease, indicating a broad market for precision radiotherapy services[38] - The Chinese radiotherapy market is projected to grow from 55.4 billion RMB in 2022 to 144.7 billion RMB by 2030, with a compound annual growth rate (CAGR) exceeding 12%[39] Strategic Initiatives - The company has established a strategic platform for tumor precision radiotherapy through its subsidiary Chengdu Yonghe Cheng Medical Technology Co., Ltd.[43] - The company is expanding its tumor precision radiotherapy chain hospitals in major cities, integrating services for screening, treatment, and rehabilitation[43] - The company utilizes a dual growth strategy of "external mergers and acquisitions + internal growth" to strengthen its tumor precision radiotherapy business[44] - The company has established a chain of specialized hospitals for tumor precision radiotherapy, acquiring four hospitals to enhance its scale and service quality[48] - The company is focusing on optimizing production processes and implementing automation to improve efficiency and product quality[49] Financial Management and Governance - The company maintains a commitment to governance and compliance, ensuring that shareholder rights are protected and that operations are conducted transparently[120] - The company established a fair and transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, enhancing operational management and economic efficiency[125] - The company has a total of 1,200 employees at the end of the reporting period, with 622 in production, 39 in sales, 308 in technology, 42 in finance, and 189 in administration[161] - The company has a cash dividend policy in place, but for the fiscal year 2023, it will not distribute cash dividends, issue bonus shares, or convert capital reserves into share capital[165] - The company has established a comprehensive quality management system to ensure high standards in medical technology and services[188] Research and Development - The number of R&D personnel decreased by 12.41% from 145 in 2023 to 127 in 2024, while the proportion of R&D personnel increased from 10.25% to 10.82%[77] - R&D investment decreased by 13.18% from ¥31,261,808.27 in 2023 to ¥27,143,055.38 in 2024, maintaining a ratio of 3.30% of operating revenue[77] - The company is committed to investing in research and development to overcome industry bottlenecks and enhance innovation capabilities[72] - The company has achieved compliance with EN13828 standards for its products, ensuring high-quality performance in heating and cooling systems[69] Community Engagement and Social Responsibility - The company actively participated in over 30 community health events and provided support to more than 1,300 cancer patients in 2024[186] - The company emphasizes the importance of community engagement through cancer prevention lectures and free screening activities to raise awareness[106] - The company has a robust employee rights protection system in place, ensuring compliance with labor laws and fostering a harmonious labor relationship[187] Risks and Challenges - The company faces risks related to foreign trade environment changes, particularly affecting its valve and pipe fittings business, which primarily exports to Europe and the US[109] - The company is exposed to exchange rate fluctuations as its valve and pipe fittings business relies heavily on exports settled in USD[110] - A significant portion of the company's hospital revenue comes from local health insurance, which may face payment delays as the business scales[113] - The company is adapting to healthcare payment reforms that could lead to revenue fluctuations and profitability challenges[114]

证券代码：002795 证券简称：永和智控 公告编号：2025-008 永和流体智控股份有限公司 关于董事、高级管理人员股份减持计划时间届满的公告 公司董事、总经理鲜中东先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 永和流体智控股份有限公司（以下简称"公司"）于2024年11月28日披露了《关 于董事、高级管理人员减持股份预披露公告》（公告编号：2024-055号），公司 董事、总经理鲜中东先生计划自减持计划公告披露之日起15个交易日后的3个月 内（2024年12月20日至2025年3月19日，根据相关法律法规规定禁止减持的期间 除外）通过集中竞价交易方式减持本公司股份不超过686,000股（占本公司总股 本比例0.15%）。 公司于近日收到鲜中东先生的《关于股份减持计划时间届满的告知函》（以 下简称"告知函"）。根据《中华人民共和国证券法》《上市公司股东减持股份管 理暂行办法》《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、 监事、高级管理人员减持股份》等有关规定，截至告知函出具之 ...

证券代码：002795 证券简称：永和智控 公告编号：2025-007 永和流体智控股份有限公司 关于公开挂牌转让全资孙公司成都山水上酒店有限公司100%股 权及债权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 永和流体智控股份有限公司（以下简称"公司"）于 2024 年 10 月 17 日召开第五 届董事会第十三次临时会议、第五届监事会第十一次临时会议，审议通过了《关于拟 公开挂牌转让全资孙公司成都山水上酒店有限公司 100%股权及债权的议案》，同意 公司在产权交易所公开挂牌转让公司全资孙公司成都山水上酒店有限公司（以下简称 "成都山水上"）100%股权及公司全资子公司成都永和成医疗科技有限公司（以下简 称"成都永和成"）对成都山水上的全部债权，并同意授权公司董事长或董事长授权的 代理人负责具体实施该事项。具体内容详见公司于 2024 年 10 月 18 日在巨潮资讯网 （http://www.cninfo.com.cn）刊登的《关于拟公开挂牌转让全资孙公司成都山水上酒 店有限公司 100%股权及债权的公告》（公告编号：2024- ...

证券代码：002795 证券简称：永和智控 公告编号：2025-006 永和流体智控股份有限公司 关于公司与全资子公司相互提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 成立日期：2003 年 08 月 28 日 经营范围：一般项目：五金产品制造；五金产品批发；五金产品研发；五金 产品零售；卫生洁具研发；卫生洁具制造；塑料制品销售；塑料制品制造；卫生 洁具销售；建筑用金属配件制造；建筑用金属配件销售；机械设备研发；机械设 备销售；专用设备制造（不含许可类专业设备制造）；技术服务、技术开发、技 术咨询、技术交流、技术转让、技术推广；第一类医疗器械销售；第二类医疗器 械销售；第一类医疗器械租赁（除依法须经批准的项目外，凭营业执照依法自主 开展经营活动）。许可项目：第三类医疗器械经营（依法须经批准的项目，经相 关部门批准后方可开展经营活动，具体经营项目以审批结果为准）。 是否是失信被执行人：否 最近一年又一期的主要财务指标如下： 永和流体智控股份有限公司（以下简称"公司"）于 2025 年 1 月 10 日召开第 五届董事会第十 ...

Financial Performance - The estimated net profit attributable to shareholders for 2024 is expected to be a loss between RMB 21 million and RMB 30 million, representing a decline of 34.52% to 92.18% compared to the loss of RMB 15.61 million in the same period last year [3]. - The estimated operating revenue for 2024 is projected to be between RMB 78 million and RMB 88 million, down from RMB 94.82 million in the previous year [3]. - The estimated basic earnings per share for 2024 is expected to be a loss between RMB 0.48 and RMB 0.69, compared to a loss of RMB 0.36 per share in the previous year [3]. Business Challenges - The decline in valve and pipe fittings business revenue and gross profit is attributed to product price reductions and rising raw material costs [5]. - Other business segments also experienced revenue declines compared to the previous year, while still incurring high depreciation and labor costs, leading to significant losses [6]. Asset Impairment - There are indications of impairment for long-term assets and goodwill related to hospital acquisitions, which will undergo impairment testing by an evaluation agency [6]. Financial Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, with the final figures to be disclosed in the official 2024 annual report [7].

证券代码：002795 证券简称：永和智控 公告编号：2025-002 永和流体智控股份有限公司 第五届董事会第十八次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 永和流体智控股份有限公司（以下简称"公司"）董事会于 2025 年 1 月 10 日 以电话及邮件方式向全体董事发出召开第五届董事会第十八次临时会议的通知。 2025 年 1 月 10 日，公司第五届董事会第十八次临时会议以通讯表决的方式召开。 本次会议应出席董事 7 名，实际出席董事 7 名。会议由董事长魏璞女士召集，公 司监事、高级管理人员列席了会议。本次会议的召集、召开程序符合《中华人民 共和国公司法》、《深圳证券交易所股票上市规则》和《公司章程》的有关规定。 具体内容详见公司同日刊登于巨潮资讯网（http://www.cninfo.com.cn）、《证 券时报》和《证券日报》的《关于公司与全资子公司相互提供担保的公告》（公 告编号：临 2025-003 号）。 三、备查文件 《永和智控第五届董事会第十八次临时会议决议》 在保证全体董事充分发表意见的 ...